secwatch.observer — SEC 8-K summary
======================================

Issuer:     10x Genomics, Inc. (TXG)
CIK:        0001770787
Form:       8-K
Filed at:   2024-10-29T23:59:59+00:00
Accession:  0001770787-24-000071
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

10x Genomics Q3 revenue $151.7M (-1% YoY); cuts FY2024 revenue guidance to $595-605M
--------------------------------------------------------------------------------

- Revenue $151.7M, down 1% YoY; net loss improved to $35.8M from $93.0M.
- FY2024 revenue guidance lowered to $595-605M from prior $640-660M (3% decline YoY midpoint).
- CEO cites greater-than-anticipated disruption from sales restructuring and cautious spending.
- Board member Mathai Mammen resigned effective Oct 24, 2024 due to professional time commitments.
- Launched GEM-X Flex, GEM-X Universal Multiplex, and Chromium Xo instruments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770787/000177078724000071/0001770787-24-000071-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770787/000177078724000071/txg-20241024.htm
  HTML page:      https://secwatch.observer/filing/0001770787-24-000071

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer